Bristol-Myers Squibb and Starboard Value square off over Celgene deal

Less than one month before shareholders vote on the deal, Bristol-Myers Squibb Co.'s proposed $74 billion acquisition of Celgene Corp. is coming under intense fire from an activist investor. Earlier this year, New York City-based Bristol-Myers Squibb (NYSE: BMY) said its acquisition of Summit, New Jersey-based Celgene (Nasdaq: CELG) would strengthen its cancer and inflammatory disease drug products. But activist investor Starboard Value said "we believe the proposed acquisition of Ce lgene is ill-advised…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news